Vir en­lists J&J vet to run busi­ness de­vel­op­ment; Gilead finds Kite suc­ces­sor to Christi Shaw

→ Af­ter grab­bing $10 mil­lion in fund­ing from the Bill & Melin­da Gates Foun­da­tion for its HIV vac­cine ear­ly this month, Vir Biotech­nol­o­gy has now plucked Jeff Calcagno as EVP and CBO. Calcagno hails from J&J, hav­ing spent 12 years with the com­pa­ny. Ear­li­er last month, George Scan­gos hand­ed in his re­tire­ment pa­pers and gave the reins of Vir to Bay­er’s Mar­i­anne De Backer.

Gilead has now filled the va­cant seat left in the wake of Christi Shaw’s ex­it from Kite with the ap­point­ment of Cindy Perettie. Perettie joins the cell ther­a­py unit as EVP of Kite — in­stead of CEO — near­ly two months af­ter Shaw stepped down, and she will be re­port­ing di­rect­ly to Daniel O’Day. Perettie for­mer­ly served as CEO of Foun­da­tion Med­i­cine and lat­er head­ed Roche’s Mol­e­c­u­lar Lab So­lu­tions af­ter Roche bought out Foun­da­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.